This week’s conversation series continues on the theme of reviewing NASH-TAG 2023, a watershed moment for Fatty Liver disease. For this wrap-up feature, Amy Articolo and Naim Alkhouri join Jörn Schattenberg and Roger Green to illustrate their enthusiasm coming out of the conference.
Surfing NASH highlights key moments from its coverage of a historic NASH-TAG conference. In this conversation, Naim Alkhouri, Amy Articolo, Jörn Schattenberg and Roger Green explore key takeaways, insights on the F3 population and using AI-assisted assessment to improve those therapeutic efficacy.
SurfingNASH reviews a riveting NASH-TAG 2023 in a two-part wrap-up episode featuring Amy Articolo, Naim Alkhouri and Donna Cryer. The panelists discuss a myriad of topics spanning across the therapeutic efficacy of resmetirom, NITs, bariatric surgery and the trajectory of regulatory science.
Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the final installment of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Naim Alkhouri, Stephen Harrison and Ian Rowe to discuss putting a dent in Fatty Liver disease in 2022 and beyond.
A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This final conversation discusses the diversity of populations with NASH before closing with the group’s predictions into a new year in the field of Fatty Liver disease.
Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green convene to recap the just-concluded 2022 AASLD Liver Meeting. The panelists touch on a range of topics from a particularly momentous event which saw many promising papers presaging an exciting upcoming year for the field of Fatty Liver.
This episode is Sponsored by Resoundant.
What are the practical benefits and challenges for clinicians wishing to deploy MRE (through MAST and/or Hepatogram along with PDFF) as an outpatient test in NASH Clinical Practice?
This episode is Sponsored by Resoundant.
How can epidemiology-driven data modeling improve our setting strategies and targets for diagnostic and drug development?
This Episode is Sponsored by Madrigal Pharmaceuticals: Once we acknowledge the potential for economic, social and medical damage that the increasing trend toward adolescent and pediatric NAFLD will cause, what solutions do we have? Can Liver Health education be effective?
This Episode is Sponsored by Madrigal Pharmaceuticals: What Can We Learn About Health Disparities In NASH Epidemiology and Treatment From the Content of NASH Connect?
Hepatologist Naim Alkhouri and Endocrinologist Scott Isaacs join Ken Cusi and Roger Green to discuss drug choices prescribers can make
